Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer

Surgery Today

Volumn 43, Issue 8, 2013, Pages 901-905

  Yamaki, Sayaka ^a   Fujii, Takaaki ^a   Yajima, Reina ^a   Hirakata, Tomoko ^a,c   Yamaguchi, Satoru ^b   Fujisawa, Tomomi ^a,c   Tsutsumi, Soichi ^a   Asao, Takayuki ^a   Yanagita, Yasuhiro ^a,c   Iijima, Misa ^c   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Japan)

^c Gunma Cancer Center   (Japan)

Author keywords

Breast cancer; Galectin 3; Ki 67; Vascular invasion

Indexed keywords

GALECTIN 3; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR INVASION;

ADULT; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84880262037     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0378-3     Document Type: Article

References (22)

1. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Keizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu F, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PW, Rini JM, Wang JL. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76:597-8.
2. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29-41.
3. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305-28.
4. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19:543-9.
5. Inohara H, Raz A. Functional evidence that cell adhesion. Cancer Res. 1995;55:3267-71.
6. Ray S, Lukyanov P, Ocheing J. Extracellular functions of galectin-3. Glycoconj J. 2004;19:527-35.
7. Newlaczyl AU, Yu LG. Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123-8.
8. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43-8.
9. Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol. 1998;12:1287-90.
10. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004;165:1931-41.
11. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenecity of human breast carcinoma cells. Clin Cancer Res. 2001;7:661-8.
12. van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;8:1096-9.
13. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185-91.
14. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H, Hirohashi S. Clinico-pathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2002;8:2570-5.
15. Takenaka Y, Knohara H, Yoshii T, Oshima K, Nakahara A, Akahani S, Honjo Y, Yamamoto Y, Raz A, Kudo T. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 2003;195:1-9.
16. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, Baba H, Maehara Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005;25:3117-22.
17. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kudo T. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6:4635-40.
18. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L, Ranelletti FO. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol. 2002;20:3850-2.
19. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, Asao T, Kuwano T. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res. 2007;27:2289-96.
20. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable progression in gastric cancer. Anticancer Res. 2006;26:1369-76.
21. Saggiorato E, Bergero N, Volante M, Bacillo E, Rosas R, Gasparri G, Oriandi F, Papotti M. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol. 2006;126:59-66.
22. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotoic nude mouse model of human breast cancer. Clin Cancer Res. 2003;9:2374-83. Science, and Technology